日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Synechocystis sp. Phosphoribosylamine--glycine ligase (purD) CSB-YP305012SSQ
CSB-EP305012SSQ
CSB-BP305012SSQ
CSB-MP305012SSQ
CSB-EP305012SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. D-alanyl-D-alanine dipeptidase (ddpX) CSB-YP305013SSQ
CSB-EP305013SSQ
CSB-BP305013SSQ
CSB-MP305013SSQ
CSB-EP305013SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Phenylalanine--tRNA ligase beta subunit (pheT), partial CSB-YP305014SSQ
CSB-EP305014SSQ
CSB-BP305014SSQ
CSB-MP305014SSQ
CSB-EP305014SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (ispD) CSB-YP305015SSQ
CSB-EP305015SSQ
CSB-BP305015SSQ
CSB-MP305015SSQ
CSB-EP305015SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Maf-like protein sll0905 (sll0905) CSB-YP305016SSQ
CSB-EP305016SSQ
CSB-BP305016SSQ
CSB-MP305016SSQ
CSB-EP305016SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. SsrA-binding protein (smpB) CSB-YP305017SSQ
CSB-EP305017SSQ
CSB-BP305017SSQ
CSB-MP305017SSQ
CSB-EP305017SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Putative diflavin flavoprotein A 3 (dfa3), partial CSB-YP305018SSQ
CSB-EP305018SSQ
CSB-BP305018SSQ
CSB-MP305018SSQ
CSB-EP305018SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Alanine--tRNA ligase (alaS), partial CSB-YP305020SSQ
CSB-EP305020SSQ
CSB-BP305020SSQ
CSB-MP305020SSQ
CSB-EP305020SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uridylate kinase (pyrH) CSB-YP305021SSQ
CSB-EP305021SSQ
CSB-BP305021SSQ
CSB-MP305021SSQ
CSB-EP305021SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. KaiC-like protein 2 (slr1942), partial CSB-YP305022SSQ
CSB-EP305022SSQ
CSB-BP305022SSQ
CSB-MP305022SSQ
CSB-EP305022SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Octanoyltransferase (lipB) CSB-YP305023SSQ
CSB-EP305023SSQ
CSB-BP305023SSQ
CSB-MP305023SSQ
CSB-EP305023SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Sulfate/thiosulfate import ATP-binding protein CysA (cysA) CSB-YP305024SSQ
CSB-EP305024SSQ
CSB-BP305024SSQ
CSB-MP305024SSQ
CSB-EP305024SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Pyrroline-5-carboxylate reductase (proC) CSB-YP305025SSQ
CSB-EP305025SSQ
CSB-BP305025SSQ
CSB-MP305025SSQ
CSB-EP305025SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Probable glutaredoxin slr1562 (slr1562) CSB-YP305026SSQ
CSB-EP305026SSQ
CSB-BP305026SSQ
CSB-MP305026SSQ
CSB-EP305026SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein sll1483 (sll1483) CSB-YP305027SSQ
CSB-EP305027SSQ
CSB-BP305027SSQ
CSB-MP305027SSQ
CSB-EP305027SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Circadian clock protein kaiB (kaiB) CSB-YP305028SSQ
CSB-EP305028SSQ
CSB-BP305028SSQ
CSB-MP305028SSQ
CSB-EP305028SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Dihydroxy-acid dehydratase (ilvD), partial CSB-YP305029SSQ
CSB-EP305029SSQ
CSB-BP305029SSQ
CSB-MP305029SSQ
CSB-EP305029SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Carbamate kinase (arcC) CSB-YP305030SSQ
CSB-EP305030SSQ
CSB-BP305030SSQ
CSB-MP305030SSQ
CSB-EP305030SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. DNA polymerase III subunit alpha (dnaE-N), partial CSB-YP305031SSQ
CSB-EP305031SSQ
CSB-BP305031SSQ
CSB-MP305031SSQ
CSB-EP305031SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechococcus elongatus Phenylalanine--tRNA ligase beta subunit (pheT), partial CSB-YP305032FPY
CSB-EP305032FPY
CSB-BP305032FPY
CSB-MP305032FPY
CSB-EP305032FPY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×